Prime Medicine, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Prime Medicine, Inc. (PRME) develops gene editing therapies using its proprietary Prime Editing platform, a next-generation technology that enables precise search-and-replace DNA modifications without double-strand breaks to treat genetic diseases across hematology, immunology and oncology, liver, and lung therapeutic areas. The company offers a pipeline of investigational programs including PM359, an ex vivo autologous hematopoietic stem cell therapy delivered via electroporation for p47phox chronic granulomatous disease (CGD) currently in Phase 1/2 trials under the Prime-0101 study and holding rare pediatric and orphan drug designations from the U.S. FDA; in vivo lipid nanoparticle (LNP)-delivered Prime Editors for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD), with PM647 nominated as the AATD development candidate in August 2025; LNP/AAV Prime Editors incorporating PASSIGE technology for cystic fibrosis; and ex vivo CAR-T cell products incorporating PASSIGE for immunology and oncology indications. Prime Medicine operates primarily in the United States, targeting patients with debilitating genetic disorders through one-time curative therapies. Founded in 2019 and headquartered in Cambridge, Massachusetts, the company recently entered a strategic license and broad collaboration agreement with Bristol Myers Squibb in September 2024 to develop and commercialize ex vivo T-cell Prime Editor products with up to $3.5 billion in potential value; secured up to $15 million from the Cystic Fibrosis Foundation in January 2024 to advance cystic fibrosis programs; appointed Matthew Hawryluk, Ph.D., M.B.A., as Chief Business Officer in November 2025 to bolster strategic partnerships; narrowed its pipeline from 18 to four core preclinical and clinical programs focused on high-value liver and lung diseases; and completed a financing round extending its cash runway while presenting new preclinical data for Wilson's Disease PM577 at the AASLD meeting in late 2025.
Company News
Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Leading Indicators For The October Breakout Cycle
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
Prime Medicine Gets FDA Green Light for Gene Editing Study
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Prime Drink Group Provides Bi-Weekly MCTO Status Report
Prime Medicine to Participate in Upcoming Investor Conferences
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME
Prime Medicine: Soon In The Clinic
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine, Inc. $PRME Shares Sold by Amova Asset Management Americas Inc.
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease